Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Maxcyte Inc (NQ: MXCT )

3.895 +0.035 (+0.91%)
Streaming Delayed Price Updated: 11:54 AM EST, Nov 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Maxcyte Inc

< Previous 1 2 3 4 5 Next >
MaxCyte to Participate in Two Upcoming Investor Conferences
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Appoints Cynthia Collins to its Board of Directors
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Earnings Preview
Via Benzinga
MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases
Kamau to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its homology-directed repair (HDR) novel gene correction technology 
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference
From MaxCyte, Inc
Via GlobeNewswire
MXCT Stock Earnings: MaxCyte Beats EPS, Beats Revenue for Q2 2024
MXCT stock results show that MaxCyte beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development
Legend Biotech obtains license to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its non-viral engineered pipeline portfolio across a variety of cell types including T... 
From MaxCyte, Inc
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Louisiana-Pacific Posts Upbeat Results, Joins Cricut, Elanco Animal, American Public Education And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
MXCT Stock Earnings: MaxCyte Beats EPS, Beats Revenue for Q1 2024
MXCT stock results show that MaxCyte beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
Be Biopharma to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform within its Engineered B Cell Medicines programs 
From MaxCyte, Inc
Via GlobeNewswire
Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket
Shares of Taysha Gene Therapies, Inc. (NASDAQ: TSHA) rose sharply in today’s pre-market trading after the company reported a year-over-year increase in FY23 EPS results. 
Via Benzinga
Harrow Posts Weak Q4 Results, Joins TeraWulf, Nasdaq And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were slightly lower this morning, with the Dow futures falling by around 0.1% on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
NVIDIA To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Nasdaq futures falling by around 20 points on Wednesday. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences
From MaxCyte, Inc
Via GlobeNewswire
Earnings Scheduled For March 12, 2024
Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is likely to report earnings for its fourth quarter. 
Via Benzinga
MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers
Wugen to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its programs for hematologic and solid tumor cancers 
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs
Imugene using MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support azer-cel – a potential first-in-class allogeneic CD19 CAR T product candidate for the treatment of blood cancer... 
From MaxCyte, Inc
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.